Education
About Us
Working with TipRanks
Follow Us
Nextcure (NXTC)
:NXTC
NXTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $2.57
Previous CloseN/A
Volume33.57K
Average Volume (3M)67.60K
Market Cap
$13.45M
Enterprise Value-$31.31M
Total Cash (Recent Filing)-$8.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 01, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding28,006,683
10 Day Avg. Volume114,772
30 Day Avg. Volume67,597
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-2.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.58
Forecast
1Y Price Target
$3.00Price Target Upside525.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
NextCure News
PremiumCompany Announcements
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
PremiumCompany Announcements
NextCure Reports 2024 Financials and Strategic Progress
PremiumCompany Announcements
NextCure Advances with New Cancer Drug Application---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNextCure is enrolling patients in Cohort 2 in Phase 1, which is taken as a positive signal of safety with no dose-limiting toxicities likely observed.
Preclinical EfficacyPreclinical results have demonstrated superior efficacy vs the val-cit linker MMAE ADC in ovarian cancer and breast cancer models, showing potential for LNCB74 to be more efficacious.
Proprietary TechnologyNextCure's proprietary glucuronidase linker is believed to demonstrate superior efficacy compared to similar constructs, particularly in ovarian and breast cancer models.
Bears Say
Competitive LandscapeThe B7-H4 ADC landscape is competitive with several other clinical stage players, highlighting the challenges LNCB74 may face.
Program PrioritizationNextcure has decided to halt further enrollment for NC410's Phase Ib study in CRC and ovarian cancer in order to prioritize resources on LNCB74.
Stock Price TargetAnalyst is lowering the price target to $3, given Nextcure no longer has any programs in active clinical studies.
---
Ownership Overview
―
Insiders
7.34% Mutual Funds
37.93% Other Institutional Investors
51.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NXTC FAQ
What was Nextcure’s price range in the past 12 months?
Nextcure lowest stock price was $0.47 and its highest was $2.57 in the past 12 months.
What is Nextcure’s market cap?
Nextcure’s market cap is $13.45M.
When is Nextcure’s upcoming earnings report date?
Nextcure’s upcoming earnings report date is May 01, 2025 which is in 30 days.
How were Nextcure’s earnings last quarter?
Nextcure released its earnings results on Mar 06, 2025. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.06.
Is Nextcure overvalued?
According to Wall Street analysts Nextcure’s price is currently Undervalued.
Does Nextcure pay dividends?
Nextcure does not currently pay dividends.
What is Nextcure’s EPS estimate?
Nextcure’s EPS estimate is -0.4.
How many shares outstanding does Nextcure have?
Nextcure has 28,006,683 shares outstanding.
What happened to Nextcure’s price movement after its last earnings report?
Nextcure reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went up 5.634%.
Which hedge fund is a major shareholder of Nextcure?
Currently, no hedge funds are holding shares in NXTC
---
Company Description
Nextcure
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
---
NXTC Stock 12 Month Forecast
Average Price Target
$3.00
▲(525.00% Upside)
Technical Analysis
GlycoMimetics
―
Carisma Therapeutics
―
Moleculin Biotech
―
Hookipa Pharma
―
SAB Biotherapeutics
―
Best Analysts Covering NXTC
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-40.52%
reiterated a buy rating 26 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -40.52% per trade.
---